# Efficacy and Safety of AQX-1125 in IC/BPS

> **NCT01882543** · PHASE2 · COMPLETED · sponsor: **Aquinox Pharmaceuticals (Canada) Inc.** · enrollment: 69 (actual)

## Conditions studied

- Interstitial Cystitis
- Bladder Pain Syndrome

## Interventions

- **DRUG:** AQX-1125
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01882543
- **Lead sponsor:** Aquinox Pharmaceuticals (Canada) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01882543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01882543, "Efficacy and Safety of AQX-1125 in IC/BPS". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01882543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*